Alchemab was delighted to see this article in Alzforum highlighting Alchemab’s unique platform and preclinical Alzheimers candidate ATLX-1088 targeting CD33. This article explores data that Ralph Minter, our Senior Vice President of Research, presented at AD/PD –Advances in Science & Therapy 2024 International Conference on Alzheimer’s and Parkinson’s Diseases.
Listen to our CEO, Young Kwon discuss Alchemab’s innovative platform and its novel approach to drug discovery on the pharmaphorum podcast. Learn More.
Our CEO Young Kwon was delighted to speak with Richard Staines of the Optimum Perspectives Podcast on how Alchemab is revolutionizing antibody drug discovery with a novel alternative to the classic “choose a target” approach.
Alchemab CEO Young Kwon and Taylor Mixides from Drug Target Review discuss how Alchemab’s research has significant potential to transform the landscape of neurodegenerative disease research and improve the lives of those affected by these challenging conditions.
Alchemab was delighted to be featured in Drug Target Review in a profile by Izzy Wood. In the article, Izzy and Olivia Cavlan, our Chief Corporate Development and Strategy Officer, discuss the untapped potential of AI in drug target discovery and how Alchemab’s platform aims to identify common antibodies in resilient individuals and uncover the […]
Our Co-Founder and CSO Jane Osbourn was delighted to speak with her longtime friend Ahuva Nissim, antibody and therapeutic engineering professor at William Harvey Research Institute, Queen Mary University of London, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent protective antibodies. She […]
Thank you to Nature Biotechnology for including Alchemab in NBT’s Class of 2021 biotechs! Their article features an interview with Jane Osbourn, Olivia Cavlan and Young Kwon alongside some very exciting startups.
Many thanks to Chloe Kent at In Vivo for her great interview with our CEO Young Kwon. In her story, titled Alchemab Is Bringing A New Meaning To Patient Centered Care, Chloe explores how the first step in our drug discovery journey starts with individual patients. As we target diseases across neurology and oncology through […]
Alchemab was delighted to be featured in Nature Biotechnology in a profile by Michael Eisenstein. In the article he speaks with Young Kwon, our CEO, and Jane Osbourn, our founder and CSO, about Alchemab’s revolutionary approach of looking for protective antibodies in ‘resilient’ people which may provide a new approach for discovering drug targets: “Our […]
We are delighted to announce the winners of the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.